Diving into the complex world of microbiome research, I had the privilege of speaking with Ivan Kairatov, a renowned biopharma expert with extensive experience in technology and innovation within the industry. With a strong background in research and development, Ivan has been instrumental in
Imagine a world where life-altering therapies for genetic disorders, cancer, and infectious diseases are not just a distant dream but a tangible reality, delivered precisely to the cells that need them most. RNA therapeutics hold this transformative promise, yet their potential remains locked
Ivan Kairatov has spent years at the crossroads of oncology and drug development, translating trial signals into day-to-day decisions for patients with localized prostate cancer. In this conversation, he unpacks new evidence showing that most of the value from androgen deprivation therapy (ADT)
A therapy that should unleash the immune system instead fuels a tumor’s growth, and the only way to see why is to listen to each cell speak for itself; that is the everyday paradox that single-cell RNA sequencing (scRNA-seq) now makes decipherable in real time. In oncology, this shift from average
In cancer trials where survival curves dominate headlines yet leave the lived experience in the margins, a new consensus promises to pull patient voices into the center of decision-making by standardizing how those voices are captured, analyzed, and reported. Patient-reported outcomes (PROs) have
Imagine starting each day with a steaming cup of tea, a ritual cherished by millions worldwide for its soothing aroma and perceived wellness perks. Yet, beneath this comforting habit lies a complex debate: Is tea truly a health elixir, or does it harbor hidden risks? This roundup dives into the
